Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 3NIH 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 76Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Burkitt Lymphoma 17Recurrence 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms, Plasma Cell 5Lymphoma 5Leukemia, Biphenotypic, Acute 5Immunoglobulin Light-chain Amyloidosis 5Smoldering Multiple Myeloma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Leukemia 4Neoplasm Metastasis 3Down Syndrome 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Hairy Cell 2Hodgkin Disease 2Fatigue 2Brain Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2

Interventions

Dexamethasone 13daratumumab 7Bortezomib 7Cyclophosphamide 6Calcium Dobesilate 5ixazomib 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4venetoclax 3belantamab mafodotin 3Specimen Handling 34-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 3pomalidomide 2isatuximab 2X-Rays 2Polymerase Chain Reaction 2Phantoms, Imaging 2Magnetic Resonance Spectroscopy 2Clinical Protocols 2Biopsy 2siltuximab 1Valganciclovir 1Tissue Banks 1Therapeutics 1Stem Cell Transplantation 1Spectrometry, Fluorescence 1Positron-Emission Tomography 1Pharmaceutical Preparations 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × Calcium Dobesilate × 1 year × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03283917 2026-02-27

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
21 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Emory University

Phase 1 Active not recruiting
11 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡